Award and Exercise of Nil Cost Options under VCP

RNS Number : 2999A

Assura PLC

25 September 2015

 

25 September 2015

Assura plc

Award and Exercise of Nil Cost Options under VCP

Assura plc ("Assura"), the leading primary care property investor and developer announces that, following the completion of the first measurement period of the Assura Group Value Creation Plan ("VCP") on 20 August 2015, Nil Cost Options were today awarded to persons discharging managerial responsibilities ("PDMRs") and staff over 24,999,950 shares in Assura calculated in accordance with the Rules of the VCP. On 25 September 2015, all PDMRs and staff exercised that element of their awards (50% by number) which is exercisable under the Rules of the VCP. The remaining nil cost options are exercisable subject to the achievement of performance hurdles in 2016 and 2017.

The table below shows the number of nil cost options awarded to PDMRs, the amount they have subsequently exercised and the amount of shares they will receive after deduction of income tax and national insurance liabilities.

	Number of Nil Cost Options awarded	Number of Nil Cost Options exercised	Number of shares receivable after deduction of Income Tax and National Insurance
Graham Roberts (Chief Executive)	11,779,255	5,889,628	3,121,503
Jonathan Murphy (Finance Director)	5,153,423	2,576,712	1,365,657
Andrew Darke	5,889,627	2,944,814	1,560,751
Paul Carroll	309,203	154,602	81,939
Spencer Kenyon	282,701	141,351	75,308
Carolyn Jones	229,693	114,847	62,799

On 25 September Andrew Darke, Paul Carroll, Spencer Kenyon and Carolyn Jones, being PDMRs (but not directors) in the Company, entered into irrevocable commitments to sell 750,000, 81,939, 75,308 and 62,799 shares respectively. The sales will take place over a number of days and the price achieved will be announced after the sales are completed.

The income tax and national insurance liabilities arising for individuals are recovered from the individuals through the cancellation of the relevant number of shares or through deduction from the proceeds of the share disposals. In the case of Graham Roberts and Jonathan Murphy, who are not making any disposals, the relevant market price for taxation purposes is 52.875 pence per share being the mid-market price at close of business on 24 September. For the remaining PDMRs the income tax and NI liabilities are dependent on the price achieved on the disposals.

As a result of the above, the increases in the shareholdings of the PDMRs are as follows:

Directors

	Shareholding on 23 September 2015	Shareholding  post exercise
Graham Roberts (Chief Executive)	3,100,000	6,221,503
Jonathan Murphy (Finance Director)	534,947	1,900,604

Other PDMRs

	Shareholding on 23 September 2015	Shareholding  post exercise and disposal
Andrew Darke	147,988	958,739
Paul Carroll	-	-
Spencer Kenyon	38,571	38,571
Carolyn Jones	-	-
Orla Ball	-	-

This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

- Ends -

For more information, please contact:

Assura plc	Tel: [phone]
Orla Ball Carolyn Jones
Finsbury	Tel: [phone]
Gordon Simpson

Notes to Editors

Assura is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington and listed on the London Stock Exchange, works with GPs, health professionals and the NHS to create innovative property solutions in order to facilitate delivery of high quality patient care in the community. At 31 March 2015, Assura's property portfolio was valued at £931 million.

Further information is available at www.assuraplc.com .

 

END

 

 

STRPGUQCBUPAGQA